Early-phase trials of the experimental RAS inhibitor daraxonrasib have shown high response and disease control rates in first-line metastatic pancreatic cancer, both as monotherapy and in combination ...
MedPage Today on MSN
Novel drug impresses in metastatic pancreatic cancer
"We need to focus on getting these drugs to patients quickly," expert says ...
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the ...
The oral presentation is titled “ The RAS:PI3Ka breaker BBO-10203 inhibits PI3Ka/AKT activity in HER2AMP models through non-canonical RAS signaling blockade .” A copy of the presentation will be ...
President Donald Trump said Tuesday he doesn't want to extend a rapidly expiring ceasefire in the U.S.-Israeli war on Iran ...
Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current ...
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results